Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen-specific immunotherapy

Clinical and Experimental Allergy

Volumn 46, Issue 3, 2016, Pages 439-448

  Schulten, V ^a   Tripple, V ^a   Aasbjerg, K ^b   Backer, V ^c   Lund, G ^d   Wurtzen P A ^d   Sette, A ^a   Peters, B ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d ALK ABELLÓ   (Denmark)

Author keywords

SCIT; SLIT; T cell; Timothy grass allergy

Indexed keywords

ALLERGEN; ALUTARD; GAMMA INTERFERON; GRASS POLLEN VACCINE; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 5; CYTOKINE;

ADULT; ALLERGEN SPECIFIC IMMUNOTHERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; BLOOD DONOR; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GRASS POLLEN; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; IN VITRO STUDY; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC VARIATION; PHLEUM PRATENSE; POLLEN ALLERGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TIME TO TREATMENT; TREATMENT DURATION; YOUNG ADULT; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; POACEAE; POLLEN; PROCEDURES; SUBLINGUAL IMMUNOTHERAPY;

ADULT; ALLERGENS; CASE-CONTROL STUDIES; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; POACEAE; POLLEN; SUBLINGUAL IMMUNOTHERAPY; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84959056916     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12653     Document Type: Article

References (34)

1. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007; 28:3-9.
2. Cibella F, Ferrante G, Cuttitta G et al. The burden of rhinitis and rhinoconjunctivitis in adolescents. Allergy, Asthma Immunol Res 2015; 7:44-50.
3. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold-high cost to society. Allergy 2010; 65:776-783.
4. Logsdon SL, Oettgen HC. Anti-IgE therapy: clinical utility and mechanistic insights. Curr Top Microbiol Immunol 2015; 388:39-61.
5. Ilmarinen P, Kankaanranta H. Eosinophil apoptosis as a therapeutic target in allergic asthma. Basic Clin Pharmacol Toxicol 2014; 114:109-117.
6. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 1:1572-1573.
7. Fitzhugh DJ, Lockey RF. Allergen immunotherapy: a history of the first 100 years. Curr Opin Allergy Clin Immunol 2011; 11:554-559.
8. Nelson HS, Norman PS. Allergen-specific immunotherapy. Chem Immunol Allergy 2014; 100:333-338.
9. Didier A, Malling HJ, Worm M et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013; 43:568-577.
10. Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717-725, e5.
11. Erekosima N, Suarez-Cuervo C, Ramanathan M et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014; 124:616-627.
12. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011; 127:64-71, 71 e1-4.
13. Nelson H, Blaiss M, Nolte H, Wurtz SO, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy 2013; 68:252-255.
14. Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract 2014; 2:144-149; quiz 50-1.
15. Nelson H, Cartier S, Allen-Ramey F, Lawton S, Calderon MA. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. J Allergy Clin Immunol Pract 2015; 3:256-266 e3.
16. Mobs C, Ipsen H, Mayer L et al. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. J Allergy Clin Immunol 2012; 130:1108-1116 e6.
17. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-713.
18. Bahceciler NN, Cobanoglu N. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma. Immunotherapy 2011; 3:747-756.
19. Aasbjerg K, Backer V, Lund G et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy 2014; 44:417-428.
20. Wurtzen PA, Lund L, Lund G, Holm J, Millner A, Henmar H. Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity. Int Arch Allergy Immunol 2007; 144:287-295.
21. Schulten V, Greenbaum JA, Hauser M et al. Previously undescribed grass pollen antigens are the major inducers of T helper 2 cytokine-producing T cells in allergic individuals. Proc Natl Acad Sci USA 2013; 110:3459-3464.
22. Schulten V, Tripple V, Sidney J et al. Association between specific timothy grass antigens and changes in T1- and T2-cell responses following specific immunotherapy. J Allergy Clin Immunol 2014; 5:1076-83.
23. Oseroff C, Sidney J, Kotturi MF et al. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol 2010; 185:943-955.
24. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10:170-181.
25. Wambre E, DeLong JH, James EA, LaFond RE, Robinson D, Kwok WW. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol 2012; 129:544-551, 51 e1-7.
26. Suarez-Fueyo A, Ramos T, Galan A et al. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. J Allergy Clin Immunol 2014; 133(130-8):e1-e2.
27. Cosmi L, Santarlasci V, Angeli R et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy 2006; 36:261-272.
28. Fanta C, Bohle B, Hirt W et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 1999; 120:218-224.
29. Benjaponpitak S, Oro A, Maguire P, Marinkovich V, DeKruyff RH, Umetsu DT. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999; 103:468-475.
30. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154:4187-4194.
31. Wambre E, DeLong JH, James EA et al. Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner. J Allergy Clin Immunol 2014; 133:872-879 e7.
32. Couroux P, Patel D, Armstrong K, Larche M, Hafner RP. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy 2015; 45:974-81.
33. Becattini S, Latorre D, Mele F et al. T cell immunity. Functional heterogeneity of human memory CD4(+) T cell clones primed by pathogens or vaccines. Science 2015; 347:400-406.
34. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.